Example: Heart Attack

Search clinical trials for: Dimethyl Sulfoxide

Total 57 results

NCT00317070

Terminated

Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)

Conditions: Interstitial Cystitis; Bladder Diseases
NCT02078284

Completed

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Conditions: Thrombocytopenia
NCT01069263

Unknown status

Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis

Conditions: Interstitial Cystitis
NCT04492306

Recruiting

Clinical Evaluation of Dimethyl Sulfoxide Dentin Pre-treatment

Conditions: Dental Diseases
NCT04439357

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT04439318

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT04439279

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT00583219

Completed

Botulin-A Toxin Instillations and Overactive Bladder

Conditions: Overactive Bladder; Detrusor Instability; Detrusor Hyperreflexia
NCT02206477

Unknown status

DMSO for Prevention of Capsular Contraction in Alloplastic Breast Reconstruction

Conditions: Breast Capsular Contracture; Dimethyl Sulfoxide
NCT04705714

Enrolling by invitation

Antibacterial and Anti-biofilm Activity of Frankincense Extract Against Porphyromonas Gingivalis

Conditions: Periodontal Diseases
NCT04439292

Active, not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT03814343

Recruiting

Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis

Conditions: Fungal Infection; Onychomycosis; Fungus, Nail
NCT03794297

Withdrawn

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Conditions: Erdheim-Chester Disease
NCT02281760

Completed

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Conditions: BRAF V600E Mutation
NCT01074567

Unknown status

DMSO Efficacy in IC/PBS Patients During and After Treatment

Conditions: Cystitis, Interstitial
NCT00667095

Terminated

Over Active Bladder Instillation Study - Botox

Conditions: Overactive Bladder; Urinary Urge Incontinence; Urinary Incontinence; Detrusor Hyperreflexia; Urge Incontinence
NCT03919071

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Conditions: Anaplastic Astrocytoma; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade III Glioma
NCT02196181

Active, not recruiting

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Conditions: Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
NCT01902173

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma
NCT02032134

Terminated

Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia

Conditions: Thrombocytopenia; Primary Thrombocytopenia,Unspecified; Thrombocytopenia Chemotherapy Induced
NCT03716583

Recruiting

Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer

Conditions: Radiation Dermatitis; Radiation Dermatitis Acute; Breast Cancer
NCT01123915

Terminated

A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People

Conditions: HIV Infections
NCT04527549

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
NCT04557956

Not yet recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8
NCT01459393

Completed

Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment

Conditions: Actinic Keratosis